Cabozantinib overcomes crizotinib resistance in ROS1 fusion positive cancer

PURPOSE: ROS1 rearrangement leads to constitutive ROS1 activation with potent transforming activity. In an ongoing phase 1 trial, the ALK tyrosine kinase inhibitor (TKI) crizotinib shows remarkable initial responses in patients with non-small cell lung cancer (NSCLC) harboring ROS1 fusions; however,...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Cancer Res
Päätekijät: Katayama, Ryohei, Kobayashi, Yuka, Friboulet, Luc, Lockerman, Elizabeth. L., Koike, Sumie, Shaw, Alice T., Engelman, Jeffrey A., Fujita, Naoya
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2014
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4286456/
https://ncbi.nlm.nih.gov/pubmed/25351743
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-1385
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia